Treatment of schizophrenia with ergot derivatives

C. A. Tamminga, M. H. Schaffer

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

Seven neuroleptic-free schizophrenic patients received bromocriptine and eight schizophrenic patients received CF 25-397, both ergot derivatives with dopamine agonist activity. Psychosis failed to improve in response to either drug at the relatively low doses administered. Unlike the antipsychotic property of apomorphine at low dose levels, neither of these ergot drugs improved schizophrenic symptomatology.

Original languageEnglish (US)
Pages (from-to)239-242
Number of pages4
JournalPsychopharmacology
Volume66
Issue number3
DOIs
StatePublished - Dec 1979

Fingerprint

Antipsychotic Agents
Schizophrenia
Bromocriptine
Apomorphine
Dopamine Agonists
Pharmaceutical Preparations
Psychotic Disorders
Therapeutics

Keywords

  • Bromocriptine
  • CF 25-397
  • Dopamine
  • Ergot derivatives
  • Schizophrenia

ASJC Scopus subject areas

  • Pharmacology

Cite this

Treatment of schizophrenia with ergot derivatives. / Tamminga, C. A.; Schaffer, M. H.

In: Psychopharmacology, Vol. 66, No. 3, 12.1979, p. 239-242.

Research output: Contribution to journalArticle

Tamminga, C. A. ; Schaffer, M. H. / Treatment of schizophrenia with ergot derivatives. In: Psychopharmacology. 1979 ; Vol. 66, No. 3. pp. 239-242.
@article{3dffe0f9f6af4d20b6d83430514f634e,
title = "Treatment of schizophrenia with ergot derivatives",
abstract = "Seven neuroleptic-free schizophrenic patients received bromocriptine and eight schizophrenic patients received CF 25-397, both ergot derivatives with dopamine agonist activity. Psychosis failed to improve in response to either drug at the relatively low doses administered. Unlike the antipsychotic property of apomorphine at low dose levels, neither of these ergot drugs improved schizophrenic symptomatology.",
keywords = "Bromocriptine, CF 25-397, Dopamine, Ergot derivatives, Schizophrenia",
author = "Tamminga, {C. A.} and Schaffer, {M. H.}",
year = "1979",
month = "12",
doi = "10.1007/BF00428312",
language = "English (US)",
volume = "66",
pages = "239--242",
journal = "Psychopharmacology",
issn = "0033-3158",
publisher = "Springer Verlag",
number = "3",

}

TY - JOUR

T1 - Treatment of schizophrenia with ergot derivatives

AU - Tamminga, C. A.

AU - Schaffer, M. H.

PY - 1979/12

Y1 - 1979/12

N2 - Seven neuroleptic-free schizophrenic patients received bromocriptine and eight schizophrenic patients received CF 25-397, both ergot derivatives with dopamine agonist activity. Psychosis failed to improve in response to either drug at the relatively low doses administered. Unlike the antipsychotic property of apomorphine at low dose levels, neither of these ergot drugs improved schizophrenic symptomatology.

AB - Seven neuroleptic-free schizophrenic patients received bromocriptine and eight schizophrenic patients received CF 25-397, both ergot derivatives with dopamine agonist activity. Psychosis failed to improve in response to either drug at the relatively low doses administered. Unlike the antipsychotic property of apomorphine at low dose levels, neither of these ergot drugs improved schizophrenic symptomatology.

KW - Bromocriptine

KW - CF 25-397

KW - Dopamine

KW - Ergot derivatives

KW - Schizophrenia

UR - http://www.scopus.com/inward/record.url?scp=0018621360&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0018621360&partnerID=8YFLogxK

U2 - 10.1007/BF00428312

DO - 10.1007/BF00428312

M3 - Article

VL - 66

SP - 239

EP - 242

JO - Psychopharmacology

JF - Psychopharmacology

SN - 0033-3158

IS - 3

ER -